All In Biotech

Drug Trial Radar · NCT06071767

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

36

Planned (sponsor's estimate)

Start

Apr 1, 2024

Primary completion

Apr 29, 2028

Study completion Aug 1, 2029

Sponsor

Sponsor type
NIH
Collaborators
University of Oxford; Gilead Sciences
First posted
Oct 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).

Conditions

  • HIV-1-infection

Interventions

  • ChAdOx1.tHIVconsv1Biological

    Administered as 0.4 mL intramuscularly (IM) at Week 0

  • ChAdOx1.HIVconsv62Biological

    Administered as 0.3 mL IM at Week 0

  • MVA.tHIVconsv3Biological

    Administered as 0.3 mL IM at Week 4

  • MVA.tHIVconsv4Biological

    Administered as 0.5 mL IM at week 4

  • Vesatolimod (VES)Drug

    VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.

  • GS-5423Drug

    Administered via intravenous (IV) infusion at week 7

  • GS-2872Drug

    Administered via IV infusion at week 7

  • MVA.tHIVconsv4Biological

    Administered 0.5 mL IM at week 60

  • PlaceboBiological

    Placebos for vaccines, VES, and bnAbs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of any serious adverse event (AE), Grade 3 or higher AE, or AE that leads to permanent discontinuation of study treatment regardless of grade, that is related to ChAdOx1-MVA/HIVconsvX vaccines, vesatolimod, GS-5423 or GS-2872Time frame: Week 0 to Week 64
  2. Proportion of participants with viral control during an ATI defined as remaining off ART with HIV-1 RNA <1,000 copies/mL at Week 16 following ATI.Time frame: Week 0 to Week 16 on Step 2

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, San Diego AntiViral Research Center CRS

    San Diego, California

  • Ponce de Leon Center CRS

    Atlanta, Georgia

  • Northwestern University CRS

    Chicago, Illinois

  • Massachusetts General Hospital CRS (MGH CRS)

    Boston, Massachusetts

  • Washington University Therapeutics CRS

    St Louis, Missouri

  • Chapel Hill CRS

    Chapel Hill, North Carolina

  • Ohio State University CRS

    Columbus, Ohio

  • Penn Therapeutics CRS

    Philadelphia, Pennsylvania

  • Houston AIDS Research Team CRS

    Houston, Texas

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

    Rio de Janeiro, Brazil, Brazil

  • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS

    Porto Alegre, Rio Grande do Sul, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.